Tempus AI Beheer
Beheer criteriumcontroles 2/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Eric Lefkofsky
Algemeen directeur
US$41.5m
Totale compensatie
| Percentage CEO-salaris | 1.89% |
| Dienstverband CEO | no data |
| Eigendom CEO | 22.8% |
| Management gemiddelde ambtstermijn | 4.9yrs |
| Gemiddelde ambtstermijn bestuur | 5.4yrs |
Recente managementupdates
Recent updates
Narratiefupdate • Sep 03
TEM: MRD And Oncology Data Platforms Balance Oncology Demand And Execution Risk
Tempus AI's updated analyst price target has moved higher to reflect a revised fair value estimate of $66.73. Analysts highlight improving modeled profit margins, a slightly lower discount rate, and fresh research pointing to the value of its precision oncology platform and data driven applications.
Narratiefupdate • Aug 28
Tempus AI: The Data Flywheel Is Starting to Work
My original thesis on Tempus AI was that this isn’t simply another AI software company. It’s building a healthcare data platform where diagnostics generate data, that data improves its AI products, and better products attract more customers and generate even more data.Seeking Alpha • Aug 18
Tempus AI: The Data Flywheel Has Started Spinning
Summary Tempus AI reported its first GAAP profit, accelerated data business growth, and raised 2026 revenue guidance to $1.595B–$1.605B (+25% Y/Y). Operating leverage from oncology volume and a mix shift to high-margin Data & Apps (72%-75% GM) drove profitability improvement and narrowed cash outflows. FDA approval for xT CDx and higher xF liquid biopsy ASPs is expected to add ~$400M incremental revenue by 2028, with the Personalis acquisition targeting MRD leadership. At 6.1x FY2026E EV/sales, valuation remains rich, but TEM’s defensive data assets and high-growth execution support a maintained 'Buy' rating. Read the full article on Seeking AlphaNarratiefupdate • Aug 15
TEM: MRD And Oncology Data Platforms Will Drive Future Oncology Demand
Analysts have trimmed the average price target on Tempus AI to about $62.64 from $66.53, reflecting updated views on slower progress toward profitability, a higher implied discount rate, and the near term financial impact of the pending Personalis acquisition, even as some remain encouraged by MRD growth and long term oncology data opportunities. Analyst Commentary Recent research updates on Tempus AI give you a mixed picture.
Narratiefupdate • Aug 01
TEM: Personalis Acquisition Risk May Limit Early Healthcare AI Upside
Tempus AI's updated Analyst Price Target framework shifts fair value to $35.65, reflecting analysts' incorporation of the Personalis acquisition terms, updated diagnostics group targets, and more cautious assumptions on discount rate and future P/E, even as they highlight Tempus AI's role in precision oncology and healthcare AI. Analyst Commentary Recent research on Tempus AI highlights a mix of enthusiasm around its positioning in healthcare AI and precision oncology, alongside a clear line of caution on valuation, execution around acquisitions, and the pace of growth needed to justify current expectations.Narratiefupdate • Jul 11
TEM: Early Healthcare AI Theme And Profit Concerns May Restrain Upside
Tempus AI's analyst fair value estimate has shifted from about $58.00 to $37.83 as analysts factor in slightly softer revenue growth, more modest long term profit margin expectations, and a lower future P/E multiple, while still acknowledging the company's differentiated oncology data platform and early position in healthcare AI. Analyst Commentary Recent research on Tempus AI points to a split view.
Narratiefupdate • Jun 27
TEM: FDA Approvals And Data Platform Progress Will Drive Future Upside
The analyst fair value estimate for Tempus AI has shifted from about $105.00 to roughly $95.45, as analysts recalibrate assumptions on revenue growth, profit margins, discount rate, and future P/E in light of recent mixed research that praises the company's differentiated data platform while questioning the clarity and timing of long term monetization. Analyst Commentary Recent Street research on Tempus AI points to a mixed but active debate, with several bullish analysts highlighting strengths in the company’s data platform and potential for execution on its long term roadmap.Analyse-artikel • Jun 19
Tempus AI (TEM) Stock Could Be 22.9% Undervalued After ECG AF Validation
Tempus AI (TEM) is back in focus after publishing a multi site validation of its FDA cleared ECG AF software, which predicts one year atrial fibrillation or flutter risk in older adults without prior AF. See our latest analysis for Tempus AI. Tempus AI’s shares have picked up momentum recently, with a 1 month share price return of 10.81% and a 7 day gain of 6.32%. However, the year to date share price return is still down 18.47% and the 1 year total shareholder return has declined 25.57%...Narratiefupdate • Jun 13
TEM: FDA Progress And Data Platforms Will Drive Future Oncology Demand
Tempus AI's analyst price targets have shifted lower to around $66.53, reflecting a mix of downward revisions and more cautious views on long term monetization from several firms, even as others acknowledge the company's differentiated data offering. Analyst Commentary Recent research paints a mixed picture around Tempus AI, with views split on how quickly the company can translate its differentiated data assets into predictable cash flows and what that should mean for valuation.Nieuw narratief • Jun 09
An Overlooked AI Play That’s Quietly Building a Healthcare Data Empire
Tempus AI isn't simply an AI software business (not another ChatBot). It's building a healthcare data platform where diagnostics, genomic testing, clinical data, and AI applications reinforce each other through a powerful network effect.Narratiefupdate • May 30
TEM: FDA Approvals And Partnerships Will Support Future Oncology Data Demand
Narrative Update The average analyst price target for Tempus AI has moved lower by several dollars to reflect a mix of reduced targets from H.C. Wainwright, BTIG, Baird, Guggenheim, and Morgan Stanley, partially offset by modest upward revisions and an upgrade from TD Cowen and TD Securities. Analysts are incorporating recent results, updated models, and ongoing partnership activity into their assessments.Narratiefupdate • May 13
TEM: Data Partnerships And Backlog Will Support Future Oncology Data Upside
Tempus AI's analyst price target is now $67.20, down from $72.40, as analysts adjust their models to reflect more moderate revenue growth assumptions and mixed recent price target revisions across the Street. Analyst Commentary Recent research on Tempus AI shows a mix of optimism and caution as analysts update their models, adjust price targets, and refine views following Q4 results and new coverage initiations.Narratiefupdate • Apr 28
TEM: Data Partnerships And Backlog Will Support Future Oncology Data Monetization
Analysts have slightly reduced the blended price target on Tempus AI to $72.40. This reflects updated models around revenue growth, profit margins and P/E assumptions after a mix of target cuts and increases across recent research, including responses to Q4 results and ongoing partnership momentum.Narratiefupdate • Apr 13
TEM: Data Partnerships And Backlog Will Support Future Precision Oncology Leadership
Narrative Update on Tempus AI The updated analyst price target for Tempus AI moves to $72.73 from $77.93, as analysts factor in slightly higher discount rates and a lower future P/E multiple. They still point to ongoing partnerships and data backlog as key supports for the long term story.Narratiefupdate • Mar 26
TEM: Data Partnerships And Backlog Will Drive Future Precision Oncology Execution
Analysts report a modestly adjusted fair value estimate of $77.93 per share for Tempus AI, reflecting mixed price target revisions that weigh the impact of new partnerships and data backlog strength against updated post Q4 models and views on visibility in parts of the business. Analyst Commentary Recent Street research on Tempus AI reflects a split view, with some focusing on growth potential in precision medicine and data, and others emphasizing execution risks and visibility in parts of the business.Narratiefupdate • Mar 11
TEM: Data Partnerships And Backlog Will Support Future Precision Oncology Upside
Our updated view trims Tempus AI's implied fair value from about $86.71 to $77.93 per share, reflecting analysts' mixed price target revisions after Q4. Some highlight expanding pharma and academic partnerships and a large data backlog, while others factor in model updates, valuation resets, and questions around data upside and Ambry.Nieuw narratief • Mar 04
Heavy AI Infrastructure And Rising Costs Will Pressure Data Economics Yet Eventually Support Upside
Catalysts About Tempus AI Tempus AI provides AI driven molecular diagnostics and data products to support clinical decision making and drug development. What are the underlying business or industry changes driving this perspective?Narratiefupdate • Feb 24
TEM: Precision Oncology And AI Biomarkers Will Support Future Upside Potential
Narrative update on Tempus AI The updated analyst price target for Tempus AI has edged down by about $1 to reflect slightly lower fair value and profit margin assumptions, even as analysts highlight the company's role in precision oncology diagnostics and AI-enabled healthcare data services as a key factor in its long term revenue growth outlook. Analyst Commentary Recent research coverage on Tempus AI highlights both enthusiasm for its role in precision oncology and AI driven healthcare data, and a set of execution and valuation questions that investors are watching closely.Nieuw narratief • Feb 18
Genomics And AI Data Licensing Will Transform Long Term Oncology Outcomes
Catalysts About Tempus AI Tempus AI operates a genomics and data platform focused on Oncology and related clinical insights. What are the underlying business or industry changes driving this perspective?Narratiefupdate • Feb 10
TEM: AI Biomarker Advancements In Oncology Will Drive Future Returns
Analysts have nudged their price target on Tempus AI higher to about US$87.92, citing slightly stronger modeled revenue growth, profit margins, and a marginally lower future P/E assumption in their updated forecasts. What's in the News Tempus reported new clinical validation data for its Immune Profile Score test, indicating that the algorithmic biomarker more accurately predicts outcomes for patients receiving immune checkpoint inhibitors than several conventional biomarkers across multiple metastatic solid tumor cohorts.Narratiefupdate • Jan 26
TEM: Oncology Data Collaborations And AI Pathology Will Drive Future Returns
Analysts have kept their fair value estimate for Tempus AI steady at about US$87.92 per share, with only very small tweaks to inputs like discount rate, revenue growth, profit margins and future P/E assumptions supporting an unchanged overall target. What's in the News Tempus AI launched Paige Predict, a suite of AI pathology tools that analyze H&E whole slide images to help predict the likelihood of 123 biomarkers and oncogenic pathways across 16 cancer types, with results delivered alongside clinical reports to physicians (Product-Related Announcements).Narratiefupdate • Jan 12
TEM: Oncology Data Collaborations Will Drive Future Returns Despite Slightly Higher Risk
Analysts have trimmed their fair value estimate for Tempus AI by about US$1.00, reflecting slightly higher discount rate assumptions as well as marginally adjusted revenue growth, profit margin, and future P/E inputs. What's in the News Tempus AI plans to present ten research abstracts at the 2025 San Antonio Breast Cancer Symposium, focusing on multimodal real world data, risk stratification for CDK4/6 inhibitor plus endocrine therapy, and tumor microenvironment signatures in hormone receptor positive, HER2 negative metastatic breast cancer (Key Developments).Narratiefupdate • Dec 25
TEM: Future Oncology Data Partnerships Will Drive Profits Despite Modestly Higher Risk
Analysts have modestly reduced their price target on Tempus AI by approximately 3 dollars, reflecting slightly higher perceived risk and marginally slower long term growth expectations, partly offset by improved profit margin and a lower projected future price to earnings multiple. What's in the News Tempus AI will present ten research abstracts at the 2025 San Antonio Breast Cancer Symposium, showcasing multimodal real world data approaches to better stratify metastatic breast cancer patients and identify responders to CDK4/6 inhibitors (Key Developments).Narratiefupdate • Dec 11
TEM: Future Profit Margins Will Expand As Federal Oncology Program Catalysts Mature
Narrative Update on Tempus AI Analyst Price Target Analysts have slightly raised their price target on Tempus AI to approximately 91 dollars and 42 cents from 91 dollars, citing a marginally lower perceived risk profile and stable long term growth and profitability assumptions. What's in the News Tempus received FDA 510(k) clearance for its RNA based xR IVD sequencing assay, expanding its toolkit for drug development partners and strengthening its position as a comprehensive precision oncology platform (FDA filing).Narratiefupdate • Nov 26
TEM: Future Profit Margins Will Expand With AI-Powered Clinical Partnerships
Analysts have revised Tempus AI's price target upwards from $87.17 to $91.00, citing improved profit margin projections and a significantly lower anticipated future price-to-earnings ratio. What's in the News Tempus AI and the Institute for Follicular Lymphoma Innovation (IFLI) launched their first collaborative research study with a non-profit foundation to create a comprehensive, multi-omic dataset for follicular lymphoma.Narratiefupdate • Nov 09
TEM: Revenue Will Accelerate With New Real-World Data Partnership
Analysts have raised their price target for Tempus AI from $82.50 to $87.17, citing shifts in expected growth and profitability as supporting factors for the updated valuation. What's in the News Tempus AI announced six new abstracts accepted for presentation at the SITC Annual Meeting 2025, highlighting advances in multi-omic algorithms and biomarkers for rare and advanced cancers (Product-Related Announcements).Narratiefupdate • Oct 26
Advances In Precision Medicine And AI Will Reshape Cancer Care Futures
Analysts have raised their price target for Tempus AI from $77.55 to $82.50, citing stronger confidence in revenue growth and profitability projections. What's in the News Tempus AI and Whitehawk Therapeutics announced a multi-year collaboration to use Tempus' real-world dataset to advance biomarker-driven research and enhance oncology clinical trial design.Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$254m |
| Mar 31 2026 | n/a | n/a | -US$303m |
| Dec 31 2025 | US$41m | US$783k | -US$245m |
| Sep 30 2025 | n/a | n/a | -US$203m |
| Jun 30 2025 | n/a | n/a | -US$199m |
| Mar 31 2025 | n/a | n/a | -US$720m |
| Dec 31 2024 | US$29m | n/a | -US$745m |
| Sep 30 2024 | n/a | n/a | -US$801m |
| Jun 30 2024 | n/a | n/a | -US$790m |
| Mar 31 2024 | n/a | n/a | -US$293m |
| Dec 31 2023 | US$2k | n/a | -US$254m |
| Sep 30 2023 | n/a | n/a | -US$276m |
| Dec 31 2022 | US$2k | n/a | -US$334m |
Compensatie versus markt: De totale vergoeding ($USD 41.50M ) Eric } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 14.74M ).
Compensatie versus inkomsten: De vergoeding van Eric is gestegen terwijl het bedrijf verliesgevend is.
CEO
Eric Lefkofsky (56 yo)
no data
Tenure
US$41,495,833
Compensatie
Mr. Eric P. Lefkofsky, J.D., is Co-Founder & Chairman of Pathos AI, Inc. Mr. Lefkofsky was Executive Director of Pathos AI, Inc. Mr. Eric P. Lefkofsky is Co-Founder of Groupon, Inc. from November 2023. He...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | no data | US$41.50m | 22.76% $ 2.4b | |
| Chief Financial Officer | 5.4yrs | US$6.36m | 0.0036% $ 376.3k | |
| Executive VP and Chief Administrative & Legal Officer | 6.3yrs | US$4.55m | 0.014% $ 1.5m | |
| Chief Legal Officer | less than a year | US$6.58m | 0.0024% $ 256.5k | |
| Chief Executive Officer of Data & Apps | less than a year | US$11.60m | 0.33% $ 35.2m | |
| Chief Accounting Officer | no data | geen gegevens | 0.014% $ 1.5m | |
| Chief Technology Officer | no data | geen gegevens | geen gegevens | |
| Chief Scientific Officer | 3.9yrs | geen gegevens | geen gegevens | |
| Vice President of Investor Relations & Competitive Intelligence | no data | geen gegevens | geen gegevens | |
| Senior VP & Head of Corporate Development | 5.7yrs | geen gegevens | geen gegevens | |
| Chief People Officer | 4.3yrs | geen gegevens | geen gegevens | |
| Senior Vice President of External Affairs | 7yrs | geen gegevens | geen gegevens |
4.9yrs
Gemiddelde duur
48yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van TEM wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.9 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | no data | US$41.50m | 22.76% $ 2.4b | |
| Independent Director | 9yrs | US$199.67k | 0.059% $ 6.3m | |
| Independent Director | 7.7yrs | US$187.17k | 0.041% $ 4.3m | |
| Independent Director | 2.6yrs | US$187.25k | 0.0066% $ 694.2k | |
| Independent Director | 7.7yrs | US$187.17k | 0.012% $ 1.2m | |
| Independent Director | 6.9yrs | US$187.17k | 0.0082% $ 869.1k | |
| Independent Director | 5.4yrs | US$188.18k | 0.0062% $ 660.3k | |
| Independent Director | 5.9yrs | US$187.17k | 0.0089% $ 943.3k | |
| Member of Advisory Board | 1.4yrs | geen gegevens | geen gegevens | |
| Independent Director | 5.4yrs | US$187.17k | 0.010% $ 1.1m | |
| Advisory Board Member | 1.4yrs | geen gegevens | geen gegevens | |
| Member of Advisory Board | 1.4yrs | geen gegevens | geen gegevens |
5.4yrs
Gemiddelde duur
62yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van TEM wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.4 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/11 15:55 |
| Aandelenkoers aan het einde van de dag | 2026/09/11 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Tempus AI, Inc. wordt gevolgd door 28 analisten. 21 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Robert Bamberger | Baird |
| Michael Ryskin | BofA Global Research |